CANbridge (Suzhou) Bio-pharma Co., Ltd.
1 clinical trials · Sponsor
◉ Watch CANbridge (Suzhou) Bio-pharma Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease (NCT05447494) | CANbridge (Suzhou) Bio-pharma Co., Ltd. | 2022-07-11 |
Track CANbridge (Suzhou) Bio-pharma Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.